Curanex PharmaceuticalsCommon Stock Operating Income

Curanex PharmaceuticalsCommon Stock (CURX) currently reports a operating income of $-11M as of June 2026. That compares with $-440K in the prior-year period — down 2321.7% year over year. Use the charts on this page to explore Curanex PharmaceuticalsCommon Stock's operating income history and peer comparisons.

Curanex PharmaceuticalsCommon Stock's operating income decreased from $-440K to $-11M — a 2321.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Curanex PharmaceuticalsCommon Stock reported $-11M in operating income as of June 2026. That compares with $-440K in the prior-year period — down 2321.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Curanex PharmaceuticalsCommon Stock, and consider following CURX for alerts when major investors trade the stock.

Curanex PharmaceuticalsCommon Stock is classified in the Healthcare sector. On operating income, it currently shows $-11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CURX with unrelated industries.